a year ago

InvenireX Secures £500k to Advance PCR Laboratory Tests

  • InvenireX, a Newcastle Upon Tyne, UK-based biotech company advancing PCR laboratory tests, raised £500k in funding from DSW Ventures and XTX Ventures

  • InvenireX has developed a platform that incorporates AI and programmable DNA to enable scientists to rapidly test raw material for biomarkers

  • The company intends to use the funds to optimize the final prototype and deploy it into external R&D laboratories for further technical validation.

      • ProblemHealthcare

      "InvenireX is addressing the challenge of detecting biomarkers at extremely low concentrations in raw materials, which is crucial for early disease detection, personalized medicine, and environmental monitoring. Existing methods often require time-consuming and costly pre-processing steps, limiting their efficiency and accuracy."

      Solution

      "InvenireX has developed a platform that integrates AI and programmable DNA nanites to enable rapid testing of raw materials for biomarkers at minute concentrations without the need for pre-processing. This innovative approach could significantly enhance the speed and accuracy of biomarker detection, potentially revolutionizing fields such as early disease detection and personalized medicine."

      Covered on